Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 sept. 2024 16h30 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology to Present at Two Upcoming Investor Conferences
27 août 2024 07h00 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
13 août 2024 07h15 HE
|
Mural Oncology, Inc.
Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025 On...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 août 2024 16h15 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
31 juil. 2024 07h00 HE
|
Mural Oncology, Inc.
WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 juil. 2024 16h15 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, July 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
05 juin 2024 16h15 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 juin 2024 16h00 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, June 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
23 mai 2024 17h00 HE
|
Mural Oncology, Inc.
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 07h00 HE
|
Mural Oncology, Inc.
Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.